Get to know what's happening behind the scenes.

Learn more



Read the latest on our blog. Let's Talk Innovation.


Stay connected with us on social media.

twitter_logo_20px.jpg @JNJinnovation



Press Releases

Read our latest news.

  • Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce Agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to ...

    New Brunswick, N.J.
    January 7, 2016

    Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. today announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a Chinese domestic pharmaceutical company and subsidiary of Sino Biopharma, Ltd. focused on liver diseases, to develop, manufacture and commercialize, outside of China, undisclosed immune-modulating agents to treat human diseases, including curative treatment of chronic Hepatitis B virus (HBV) infection.

  • Johnson & Johnson Announces Completion of Novira Therapeutics, Inc. Acquisition

    New Brunswick, NJ
    December 4, 2015

    Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The transaction was originally announced on November 4, 2015. Financial terms of the transaction have not been disclosed.


  • Collaborating to Study New Treatment for Insomnia Related to Depression

    February 3, 2015

    One of the promising scientific collaborations in our neuroscience pipeline is with Minerva Neurosciences, focusing on MIN-202 – a selective orexin-2 antagonist being studied for the treatment of insomnia and potentially other disorders associated with sleep disorders such as major depressive disorder, an area of strategic focus for Janssen.



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.